| Literature DB >> 35188040 |
Stamatios Karakatsanis1, Fotios Panitsas2, Maria Arapaki2, Dimitrios Galopoulos2, John V Asimakopoulos2, Athanassios Liaskas2, Chrysovalantou Chatzidimitriou2, Marina Belia2, Elianna Konstantinou2, Ioannis Vassilopoulos2, Stamatis S Papadatos1, Sotirios Sachanas3, Maria Efstathopoulou2,3, Xanthoula Yiakoumis3, Vassilios Pardalis4, Theodoros Iliakis4, Nefeli Giannakopoulou5, Maria Dimou4, Sevastianos Chatzidavid5, George Boutsikas2, Kyriaki Petevi2, Alexandros Kanellopoulos2, Gabriella Gainaru2, Eleni Variamis5, Marina P Siakantaris2, Marie-Christine Kyrtsonis4, Eleni Plata2, Panayiotis Tsaftaridis2, Maria N Dimopoulou2, Nora-Athina Viniou5, Konstantinos N Syrigos1, Gerassimos A Pangalis3, Panayiotis Panayiotidis4, Kostas Konstantopoulos2, Maria K Angelopoulou2, Theodoros P Vassilakopoulos2.
Abstract
Serum ferritin (SF) is frequently elevated in classical Hodgkin lymphoma (cHL). We report on its prognostic significance in an unselected series of 529 cHL patients treated with state-of-the-art therapy. Higher baseline levels correlated with markers of advanced/aggressive disease. SF levels were significantly higher in male and older patients, those with high body mass index and mixed cellularity histology. The strongest correlation was recorded between SF and complement reactive protein (CRP) levels. Gender-specific SF cutoffs which provided the best discrimination in terms of freedom from progression (FFP) were identified. In multivariate analysis elevated SF levels, advanced stage and high lactate dehydrogenase (LDH) were independent prognostic factors of inferior FFP. SF also appears to retain independent prognostic significance for progression-free survival (PFS) but not for overall survival (OS). In conclusion, SF levels in cHL reflect disease activity and are associated with adverse patient outcomes.Entities:
Keywords: Chemotherapy; Hodgkin lymphoma; classical; ferritin; prognostic factors
Mesh:
Substances:
Year: 2022 PMID: 35188040 DOI: 10.1080/10428194.2021.2010054
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022